Cargando…
HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature
Through the recent conduct of the ToGA trial, HER2 has shown to be predictive for the treatment with trastuzumab in advanced gastric and gastro-oesophageal cancer. When it comes to the prognostic properties the situation is different. Despite the fact that it is more than 20 years ago since the firs...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Ivyspring International Publisher
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319979/ https://www.ncbi.nlm.nih.gov/pubmed/22481979 http://dx.doi.org/10.7150/jca.4090 |